P81 Long-term efficacy of abrocitinib in adolescents and adults with moderate-to-severe atopic dermatitis: a post hoc analysis of JADE EXTEND

Abstract Differences exist in the manifestation and disease course of atopic dermatitis (AD) between adult adolescent patients. Long-term efficacy abrocitinib (an oral, once-daily Janus kinase 1-selective inhibitor) was examined phase III extension study JADE EXTEND (NCT03422822). This interim post hoc analysis assessed treatment up to 96 weeks adolescents adults with moderate-to-severe AD who enrolled EXTEND. Eligible (aged 12 < 18 years) (≥ from trials MONO-1 (NCT03349060), MONO-2 (NCT03575871), COMPARE (NCT03720470), TEEN (NCT03796676) DARE (NCT04345367) were Patients randomized (200 mg or 100 mg) parent studies received blinded at same dose EXTEND; those receiving placebo dupilumab either 200 Analyses proportions patients achieving an Investigator’s Global Assessment score clear almost (IGA 0/1); ≥ 75%, 90% 100% improvement baseline Eczema Area Severity Index (EASI-75, EASI-90 EASI-100, respectively); 4-point Peak Pruritus Numerical Rating Scale (PP-NRS4; used permission Regeneron Pharmaceuticals Sanofi); PP-NRS no very little itch (PP-NRS Patient Oriented Measure (POEM 4). The data cutoff date 25 September 2021. included 357 1309 (excluding previously dupilumab). Age screening visit determined age categorization. Baseline severity higher than [IGA 4 (severe); 42.3% vs. 36.7%]. At week 96, responder comparable for EASI-75 (abrocitinib mg: 84.4% 85.7%; 81.3% 76.1%), PP-NRS4 69.4% 69.3%; 60.3% 59.8%) POEM 88.6%; 79.2% 80.8%), largely stringent endpoints 62.3% 61.1%; 50.7% 48.1%), EASI-100 32.5% 21.8%; 18.7% 18.7%), IGA 0/1 53.2% 55.9%; 49.3% 45.1%) 42.9% 39.5%; 33.3% 32.3%). AD, including substantial EASI-90, 0/1. Funding sources: Pfizer Inc.